| 2025-01-30 15-28-05 | Urolithin A reduces the number of TUNEL-positive cells in the Nucleus Pulposus at a dose of 25 mg/kg/day when taken for 4 weeks after an Intervertebral Disc (IVD) puncture at 8 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 15-37-02 | Urolithin A slows the reduction in Intervertebral Disc (IVD) histological score at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A |
| 2025-01-30 15-35-56 | Urolithin A slows the progressive loss of Intervertebral Disc (IVD) height at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 12 weeks of age compared to rats not fed Urolithin A |
| 2025-01-30 15-34-35 | Urolithin A slows the progression of Intervertebral Disc (IVD) degeneration at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A |
| 2025-01-30 15-34-20 | Urolithin A slows the progression of Pfirrmann Grade at a dose of 25 mg/kg/day when taken for 4 weeks after an Intervertebral Disc (IVD) puncture at 12 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 15-33-56 | Urolithin A slows the progression of Intervertebral Disc (IVD) degeneration at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 12 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 15-32-27 | Urolithin A slows the progression in Intervertebral Disc (IVD) Pfirrmann Grade at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A |
| 2025-01-30 15-31-32 | Urolithin A slows the increase in histologic score at a dose of 25 mg/kg/day when taken for 4 weeks after an Intervertebral Disc (IVD) puncture at 12 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 14-02-08 | Neuropathy and/or Chemical Radiculitis can be resolved within 12 weeks of injecting 10X Platelet-Rich Plasma (PRP) into the Intervertebral Disc (IVD) |
| 2025-01-30 15-25-18 | Urolithin A reduces the Intervertebral Disc (IVD) histological score at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 8 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 15-24-17 | Urolithin A reduces the Intervertebral Disc (IVD) Pfirrmann Grade at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 8 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 15-17-08 | Urolithin A increases the Intervertebral Disc (IVD) disc height index at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A |
| 2025-01-30 15-15-20 | Urolithin A increases the Intervertebral Disc (IVD) Collagen Type II fluorescence at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A |
| 2025-01-30 15-14-32 | Urolithin A increases the Intervertebral Disc (IVD) Aggrecan fluorescence at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A |
| 2025-01-30 15 28 41 | Urolithin A reduces the progression of Intervertebral Disc (IVD) degeneration at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 8 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 14-48-20 | The number of Hypoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) injected into the Annulus Fibrosus of a torn L5-S1 Intervertebral Disc (IVD) may positively correlate with overall improvement in quality of life after 4+ years |
| 2025-01-30 14-29-17 | The ideal single dose for injecting Hypoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into the Annulus Fibrosus of a torn L5-S1 Intervertebral Disc (IVD) to improve overall quality of life after 4+ years may be 35.9 million cells |
| 2025-01-30 14-13-16 | Sciatica is reduced by an average of 86% at 12 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into the Intervertebral Disc (IVD) |
| 2025-01-30 14-12-07 | Sciatica is reduced by an average of 79% at 6 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into the Intervertebral Disc (IVD) |
| 2025-01-30 14-08-07 | Sciatica is not significantly reduced at 3 months after after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-30 12-15-27 | Back Pain in the Lumbar Spine is reduced by an average of 71% at 12 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-30 12-13-47 | Back Pain in the Lumbar Spine is reduced by an average of 69% at 6 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-30 12-11-56 | Back Pain in the Lumbar Spine is reduced by an average of 62% at 3 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-30 12-06-46 | Injecting leukocyte-rich >10X Platelet-Rich Plasma (PRP) into a pain-generating Intervertebral Disc (IVD) is successful in 70% of patients as assessed by NRS pain score, FRI, and patient satisfaction |
| 2025-01-29 10-55-56 | Discopathy should be the term used to collectively refer to Intervertebral Disc (IVD) bulges and disc protrusions and discs with normal contours but abnormal heights and-or T2 signal intensities on Magnetic Resonance Imaging (MRI) |
| 2025-01-29 10-54-58 | Intervertebral Disc (IVD) hydration is increased by an average of 16% at 12 months after intradiscal injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) |
| 2025-01-29 10-53-58 | Intervertebral Disc (IVD) bulges, disc protrusions, and discs with normal contours but abnormal heights and-or T2 signal intensities on Magnetic Resonance Imaging (MRI) are highly likely to indicate the presence of a tear in the inner Annulus Fibrosus |
| 2025-01-29 10-52-14 | Intervertebral Disc (IVD) height is not changed at 12 months after intradiscal injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) |
| 2025-01-29 10-39-27 | A reduction in posterior Intervertebral Disc (IVD) bulge size by >= 25% correlates with better NPS scores compared with <25% at 6 months post-injection of an average of 23 million Hypoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into the Nucleus Pulposus and Annulus Fibrosus of L4-L5 or L5-S1 |
| 2025-01-29 10-20-44 | 34% of people between 20-39 have an asymptomatic degenerated Intervertebral Disc (IVD) of the Lumbar Spine |
| 2025-01-29 10-27-22 | 85% of patients have a decrease in posterior Intervertebral Disc (IVD) bulge size 6 months on average post-injection of an average of 23 million Hypoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into the Nucleus Pulposus and Annulus Fibrosus of L4-L5 or L5-S1 |
| 2025-01-29 10-17-29 | 56% of people between 20-39 have an asymptomatic bulging Intervertebral Disc (IVD) of the Lumbar Spine |
| 2025-01-29 10-19-30 | 21% of people between 20-39 have an asymptomatic herniated Intervertebral Disc (IVD) in the Lumbar Spine |